LALPATHLAB2024-04-012024-06-30 LALPATHLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member LALPATHLAB2024-04-012024-06-30in-bse-fin:OneOperatingExpenses02Member LALPATHLAB2024-06-30 LALPATHLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LALPATHLAB2024-04-012024-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539524 LALPATHLAB NOTLISTED Dr. Lal Path Labs Ltd. Equity 2024-04-01 2025-03-31 2024-08-07 2024-07-31 INR Millions First quarter 12:30:00 15:00:00 2024-08-07 2024-08-07 Not applicable Single segment The business of running laboratories for carrying out Pathological investigations of various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Immuno-chemistry, Immunology, Virology, Cytology, other pathological and radiological investigations. 2024-04-01 2024-06-30 Unaudited Consolidated 6019000000.00 206000000.00 6225000000.00 1194000000.00 0.00 0.00 1166000000.00 60000000.00 347000000.00 1959000000.00 4726000000.00 1499000000.00 0.00 1499000000.00 448000000.00 -27000000.00 421000000.00 0.00 1078000000.00 0.00 0.00 0.00 0.00 1078000000.00 -1000000.00 1077000000.00 1064000000.00 14000000.00 1063000000.00 14000000.00 835000000.00 10 12.79 12.76 0.00 0.00 12.79 12.76 i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 7 August, 2024. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter ended June 30, 2024 and they have expressed an unmodified conclusion on the aforesaid results. ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group'). iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. iv. Figures for the quarter ended 31 March, 2024 are the balancing figures between the audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December, 2023, which were subjected to limited review. v. During the quarter ended 30 June 2024, the Parent Company has issued 2,500 equity shares of face value of INR 10 each on exercise of employee stock options. Due to size constraint, we have not pasted complete note to statement of financial results. Please refer pdf file for complete notes to the statement of Financial Results for the quarter ended June 30, 2024. Fees to collection centers/channel partners 837000000.00 Other expenses 1122000000.00 Remeasurement of the defined benefit n obligations -2000000.00 -2000000.00 0.00 Exchange differences on translation of foreign operations 1000000.00 1000000.00 0.00